丙氨酸转氨酶正常的慢性乙型肝炎患者肝组织学改变的关联因素分析

Factors associated with liver histological changes in chronic hepatitis B patients with normal alanine transaminase

  • 摘要:
    背景 丙氨酸转氨酶 (alanine transaminase,ALT)持续正常的慢性乙型肝炎(chronic hepatitis B,CHB)患者肝组织仍可能存在明显纤维化/炎症,部分可隐匿进展为肝硬化和肝癌。
    目的 筛选此类患者发生明显纤维化/炎症的高危因素。
    方法 通过电子病历选取2002年8月 - 2022年8月在解放军总医院第五医学中心住院的ALT正常且经肝活检确诊的CHB患者,回顾性检索其临床资料,采用Scheuer评分评估肝纤维化(S0 ~ S4)和炎症(G0 ~ G4),以病理(肝纤维化或炎症评分)≥2分为界,将患者分为两组(有或无明显肝纤维化/炎症),多因素Logistic回归分析独立关联因素。
    结果 共纳入1 493例患者,平均年龄(36.9 ± 11.0)岁,903例(60.5%)为男性;其中608例(40.7%)表现为明显肝纤维化,388例(26.0%)表现为明显炎症。多因素Logistic回归结果显示:有乙肝家族史、年龄>30岁、天冬氨酸转氨酶(aspartate transaminase,AST)>1 × ULN(正常值上限)、血小板(platelet,PLT)≤184 × 109/L者更易出现明显肝纤维化;HBV DNA在3.5 ~ 8.0 lg IU/mL、AST>1 × ULN、总胆红素>2 × ULN、PLT≤184 × 109/L者更易出现明显肝炎症;而HBV DNA>8.0 lg IU/mL者肝纤维化或炎症的概率较低(P<0.05)。
    结论 ALT正常的CHB患者存在明显肝纤维化或炎症的比例高于预期,需结合高危因素及时启动抗病毒治疗。

     

    Abstract:
    Background Liver fibrosis or inflammatory reaction may still exist in chronic hepatitis B (CHB) patients with persistent normal alanine transaminase (ALT), and some patients may develop into cirrhosis or liver cancer insidiously.
    Objective To identify the high-risk factors associated with obvious hepatic fibrosis or inflammation in such patients.
    Methods Patients with normal ALT and biopsy-proven CHB, admitted to the Fifth Medical Center of Chinese PLA General Hospital from August 2002 to August 2022 were selected from the electronic medical record. Their clinical information was retrospectively retrieved. Hepatic fibrosis (S0-4) and inflammation (G0-4) were evaluated according to Scheuer scoring system. The patients were divided into two groups (with or without obvious liver fibrosis/inflammation) according to the pathological (inflammation or fibrosis) score ≥ 2. Multivariate logistic regression analysis was used to analyze the independent risk factors.
    Results Totally 1493 patients were enrolled, with an average age of (36.9 ± 11.0) years. Male accounted for 60.5% (903 cases). Among them, 608 (40.7%) patients presented obvious hepatic fibrosis, and 388 (26.0%) patients presented inflammation. Multivariate logistic regression showed having family history of CHB, >30 years-old, AST >1 × ULN (upper limit of normal), and PLT ≤184 × 109/L were associated with higher likelihood of obvious fibrosis. HBV DNA between 3.5-8.0 lg IU/mL, AST >1 × ULN, TBIL >2 × ULN, and PLT ≤184 × 109/L were associated with higher likelihood of obvious hepatic inflammation. Whereas, patients with HBV DNA>8.0 lg IU/mL had relatively lower likelihood of hepatic fibrosis or inflammation (all P<0.05).
    Conclusion An unexpected high proportion of obvious hepatic fibrosis or inflammation still exists in CHB with persistent normal ALT, whose antiviral treatment should be timely initiated based on high-risk factors mentioned above.

     

/

返回文章
返回